EXECUTIVE SECRETARY REPORT – March 10th, 2019

• FINANCIAL REPORT

• TEMPORARY LICENSES

• STAFF ACTIVITIES
  • Meetings with Other Health Care Boards
  • Legislature in Session
  • NASCSA Board of Directors – Yenh
  • Roseman Student Rotation – Grace Field has finished her rotation
  • MPJE Test Writing Seminar– Leo and Darla

• REPORT TO BOARD
  • Licensing software update

• BOARD RELATED NEWS
  • Upcoming NABP National Meeting

• ACTIVITIES REPORT
  • PMP Integration
  • Legislative update
<table>
<thead>
<tr>
<th>Regulation Number and Topic</th>
<th>Workshop Propose To Bd</th>
<th>30 Days To LCB W/Letter</th>
<th>LCB R0 Number Issued</th>
<th>LCB Return Date</th>
<th>30 Days Post Public Hearing</th>
<th>Public Hearing Meeting Date</th>
<th>To LCB Final W/Cov./Info</th>
<th>Secretary of State File Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>639 PMP Registration/Access</td>
<td>01/11/18</td>
<td>01/12/18</td>
<td>R013-18</td>
<td>04/30/18</td>
<td>05/03/18</td>
<td>04/12/18</td>
<td>04/12/18</td>
<td>06/07/18</td>
</tr>
<tr>
<td>639 Show Cause</td>
<td>01/11/18</td>
<td>01/12/18</td>
<td>R014-18</td>
<td>02/27/18</td>
<td>03/13/18</td>
<td>04/12/18</td>
<td>04/12/18</td>
<td>05/16/18</td>
</tr>
<tr>
<td>639.742 Vet Dispensing</td>
<td>01/11/18</td>
<td>01/12/18</td>
<td>R015-18</td>
<td>03/09/18</td>
<td>03/13/18</td>
<td>04/12/18</td>
<td>04/17/18</td>
<td>05/16/18</td>
</tr>
<tr>
<td>639.220 Schedule of Fees</td>
<td>01/11/18</td>
<td>01/12/18</td>
<td>R015-18</td>
<td>03/09/18</td>
<td>03/13/18</td>
<td>04/12/18</td>
<td>04/17/18</td>
<td>05/16/18</td>
</tr>
<tr>
<td>639.NEW Dispensing of CS in conformance with AB 474</td>
<td>03/07/18</td>
<td>03/13/18</td>
<td>R047-18</td>
<td>04/17/18</td>
<td>05/08/18</td>
<td>06/07/18</td>
<td>06/15/18</td>
<td>06/26/18</td>
</tr>
<tr>
<td>453.510 Schedule I – Adding New Substances (Fentanyl)</td>
<td>03/07/18</td>
<td>03/15/18</td>
<td>R048-18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>639.NEW (2) – Further defines CS prescribed for pain (AB474)</td>
<td>06/07/18</td>
<td>06/15/18</td>
<td>R144-18</td>
<td>07/17/18</td>
<td>07/27/18</td>
<td>09/05/18</td>
<td>12/05/18</td>
<td></td>
</tr>
<tr>
<td>639.250 – Technician Ratio (Non-dispensing)</td>
<td>09/05/18</td>
<td>10/11/18</td>
<td>12/05/18</td>
<td>01/30/19</td>
<td>R002-19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.550 – Schedule V – Adding New Substance (Cannabidiol)</td>
<td>12/05/18</td>
<td>12/26/18</td>
<td>R198-18</td>
<td>12/26/18</td>
<td>01/31/19</td>
<td>03/07/19</td>
<td>03/15/19</td>
<td></td>
</tr>
<tr>
<td>453.520 – Schedule II – Dronabinol Oral Solution</td>
<td>01/17/19</td>
<td>01/30/19</td>
<td>R001-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>639.NEW – FQHC Off-Site Dispensing</td>
<td>01/17/19</td>
<td>02/19/19</td>
<td>R004-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>639.250 – Technician Ratio (Dispensing)</td>
<td>03/07/19</td>
<td>04/11/19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
No temporary licenses were issued since the last board meeting.
This report is prepared and presented to keep interested legislators and others abreast of the activities of the Nevada State Board of Pharmacy. Following is a summary of the March 2019 Board meeting.

**Licensing Activity:**
- 21 licenses were granted for Out-of-State pharmacies.
- 32 licenses were granted for Out-of-State wholesalers.
- 5 licenses were granted for Out-of-State Medical Devices, Equipment and Gases (MDEG) companies.
- 3 licenses were granted for Out-of-State Outsourcing Facilities
- 2 licenses were granted for Nevada MDEG companies pending receipt of a favorable inspection.
- 8 licenses were granted for Nevada pharmacies pending receipt of a favorable inspection.

**Disciplinary Actions:**
- Pharmacist NR shall receive a letter of reprimand, shall pay a fine of $2750.00, and shall complete 2 additional CEU on error prevention for verifying a prescription which was labeled and dispensed to the wrong patient.
- Pharmacist JA shall receive a letter of reprimand, shall pay a fine of $750.00, and shall complete 2 additional CEU on patient counseling for failing to counsel the patient.
- Pharmaceutical Technician LP’s registration was revoked, the revocation stayed and the license placed on probation for 1 year. LP shall pay a fine of $500.00, pay an administrative fee of $1,000.00 and shall attend three of the next four meetings on discipline day.
- Pharmacist ML shall complete 4 additional CEU on pharmacy management.
- Pharmacist SP shall pay a fine of $500.00, pay an administrative fee of $1,000.00 and shall complete 4 additional CEU on cardiology or cardiac drugs for failing to speak to the prescriber before, at the time, or after declining to fill a patient’s prescription for clopidogrel.
- RP shall receive a letter of reprimand, his controlled substance registration shall be placed on probation for 12 months, and he shall pay a fine of $5,000.00, pay an administrative fee of $2,500.00 and shall establish policies and procedures. RP’s offices/clinics are subject to quarterly inspections for one year.

**Other Activity:**
- The usual Board business reports were given, including recent and future speaking engagements; reports on national meetings; and collaboration with other state agencies.
- Licensing software update was provided.
Workshop:

**Amendment of Nevada Administrative Code (NAC) 639.250: Restrictions on supervision.** The proposed amendment to NAC 639.250 will allow for an increase in pharmaceutical technician to pharmacist ratio in certain pharmacy settings.

Public Hearing:

**Amendment of Nevada Administrative Code Chapter 453 to add certain products to the controlled substances listed in schedule V in conformity with federal regulations.** (LCB File No. R198-18) The Drug Enforcement Administration (DEA) has added certain drug products which are approved by the U.S. Food and Drug Administration (FDA) and contain cannabidiol to the list of controlled substances in schedule V of the Federal Controlled Substances Act. The proposed amendment adds such drug products to the list of controlled substances in schedule V in conformity with federal regulations of the Uniform Controlled Substances Act.